Noteworthy minimally invasive surgery research from AUA 2018 also included topics such as robot-assisted versus open radical cystectomy as well as minimally invasive retroperitoneal lymph node dissection in men with testis cancer.
"Despite the potential benefits (fewer biopsies, less cost), the proposed approach to cancer detection and biopsy—that can miss 16%-40% of existing csPCa—may be difficult to justify for all patients," writes Badar M. Mian, MD.
The AUA 2018 take-home messages in outcomes also covered topics such as environmental exposures and bladder cancer and onabotulinumtoxinA (Botox) treatment for patients with overactive bladder.
Contrast-enhanced ultrasound for detecting renal cell carcinoma recurrence following albation and new protocols for low-dose computed tomography in stone patients were among the other research highlights in imaging at the AUA annual meeting.
Other penile/urethral cancer highlights from AUA 2018 included analyses of fludeoxyglucose positron emission tomography-computed tomography and the Pl3K-AKT-mTOR pathway.
Active surveillance in selected patients with localized renal masses 4 cm to 7 cm and a patient-derived xenograft system for predicting response to targeted and immune therapies in patients with metastatic RCC were among other noteworthy kidney cancer studies presented at AUA 2018.
Other bladder cancer take-home messages covered topics such as artificial intelligence and deep learning for staging of T1 disease as well as a wearable fitness tracker for collecting data on physical activity after radical cystectomy.
Three new clinical guidelines, potentially practice-changing advances in robotics and artificial intelligence, and research on hot-button public health issues such as opioid abuse were among many highlights of the AUA annual meeting in San Francisco.
Other key prostate cancer studies from AUA 2018 included updated survival data from the European Randomized Study of Screening for Prostate Cancer and a multicenter trial of MRI-targeted biopsy.
Findings from a retrospective analysis of data collected at the National Institutes of Health provide insight on how multiparametric MRI/transrectal ultrasound-fusion biopsy (“fusion biopsy”) may be affecting management patterns and outcomes for men with prostate cancer.